Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jasper J. van der Smagt is active.

Publication


Featured researches published by Jasper J. van der Smagt.


Circulation | 2006

Plakophilin-2 Mutations Are the Major Determinant of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy

J. Peter van Tintelen; Mark M. Entius; Zahurul A. Bhuiyan; Roselie Jongbloed; Ans C.P. Wiesfeld; Arthur A.M. Wilde; Jasper J. van der Smagt; Ludolf G. Boven; Marcel Mannens; Irene M. van Langen; Robert M. W. Hofstra; Luuk Otterspoor; Pieter A. Doevendans; Luz-Maria Rodriguez; Isabelle C. Van Gelder; Richard N.W. Hauer

Background— Mutations in the plakophilin-2 gene (PKP2) have been found in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC). Hence, genetic screening can potentially be a valuable tool in the diagnostic workup of patients with ARVC. Methods and Results— To establish the prevalence and character of PKP2 mutations and to study potential differences in the associated phenotype, we evaluated 96 index patients, including 56 who fulfilled the published task force criteria. In addition, 114 family members from 34 of these 56 ARVC index patients were phenotyped. In 24 of these 56 ARVC patients (43%), 14 different (11 novel) PKP2 mutations were identified. Four different mutations were found more than once; haplotype analyses revealed identical haplotypes in the different mutation carriers, suggesting founder mutations. No specific genotype–phenotype correlations could be identified, except that negative T waves in V2 and V3 occurred more often in PKP2 mutation carriers (P<0.05). Of the 34 index patients whose family members were phenotyped, 23 familial cases were identified. PKP2 mutations were identified in 16 of these 23 ARVC index patients (70%) with familial ARVC. On the other hand, no PKP2 mutations at all were found in 11 probands without additional affected family members (P<0.001). Conclusions— PKP2 mutations can be identified in nearly half of the Dutch patients fulfilling the ARVC criteria. In familial ARVC, even the vast majority (70%) is caused by PKP2 mutations. However, nonfamilial ARVC is not related to PKP2. The high yield of mutational analysis in familial ARVC is unique in inherited cardiomyopathies.


Nature Genetics | 2004

Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR.

David Ng; Nalin Thakker; Connie M. Corcoran; Dian Donnai; Rahat Perveen; Adele Schneider; Donald W. Hadley; Cynthia J. Tifft; Liqun Zhang; Andrew O.M. Wilkie; Jasper J. van der Smagt; Robert J. Gorlin; Shawn M. Burgess; Vivian J. Bardwell; Graeme C.M. Black; Leslie G. Biesecker

Lenz microphthalmia is inherited in an X-linked recessive pattern and comprises microphthalmia, mental retardation, and skeletal and other anomalies. Two loci associated with this syndrome, MAA (microphthalmia with associated anomalies) and MAA2, are situated respectively at Xq27–q28 (refs. 1,2) and Xp11.4–p21.2 (ref. 3). We identified a substitution, nt 254C→T; P85L, in BCOR (encoding BCL-6-interacting corepressor, BCOR) in affected males from the family with Lenz syndrome previously used to identify the MAA2 locus. Oculofaciocardiodental syndrome (OFCD; OMIM 300166) is inherited in an X-linked dominant pattern with presumed male lethality and comprises microphthalmia, congenital cataracts, radiculomegaly, and cardiac and digital abnormalities. Given their phenotypic overlap, we proposed that OFCD and MAA2-associated Lenz microphthalmia were allelic, and we found different frameshift, deletion and nonsense mutations in BCOR in seven families affected with OFCD. Like wild-type BCOR, BCOR P85L and an OFCD-mutant form of BCOR can interact with BCL-6 and efficiently repress transcription. This indicates that these syndromes are likely to result from defects in alternative functions of BCOR, such as interactions with transcriptional partners other than BCL-6. We cloned the zebrafish (Danio rerio) ortholog of BCOR and found that knock-down of this ortholog caused developmental perturbations of the eye, skeleton and central nervous system consistent with the human syndromes, confirming that BCOR is a key transcriptional regulator during early embryogenesis.


American Journal of Human Genetics | 2006

Hypomethylation of the H19 Gene Causes Not Only Silver-Russell Syndrome (SRS) but Also Isolated Asymmetry or an SRS-Like Phenotype

Jet Bliek; Paulien A. Terhal; Marie-José van den Bogaard; Saskia M. Maas; B.C.J. Hamel; Georgette B. Salieb-Beugelaar; Marleen Simon; Tom G. W. Letteboer; Jasper J. van der Smagt; Hester Y. Kroes; Marcel Mannens

The H19 differentially methylated region (DMR) controls the allele-specific expression of both the imprinted H19 tumor-suppressor gene and the IGF2 growth factor. Hypermethylation of this DMR--and subsequently of the H19 promoter region--is a major cause of the clinical features of gigantism and/or asymmetry seen in Beckwith-Wiedemann syndrome or in isolated hemihypertrophy. Here, we report a series of patients with hypomethylation of the H19 locus. Their main clinical features of asymmetry and growth retardation are the opposite of those seen in patients with hypermethylation of this region. In addition, we show that complete hypomethylation of the H19 promoter is found in two of three patients with the full clinical spectrum of Silver-Russell syndrome. This syndrome is also characterized by growth retardation and asymmetry, among other clinical features. We conclude that patients with these clinical features should be analyzed for H19 hypomethylation.


Circulation | 2011

Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Pathogenic Desmosome Mutations in Index-Patients Predict Outcome of Family Screening: Dutch Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Genotype-Phenotype Follow-Up Study

Moniek G.P.J. Cox; Paul A. van der Zwaag; Christian van der Werf; Jasper J. van der Smagt; Maartje Noorman; Zahir A. Bhuiyan; Ans C.P. Wiesfeld; Paul G.A. Volders; Irene M. van Langen; Douwe E. Atsma; Dennis Dooijes; Arthur van den Wijngaard; Arjan C. Houweling; Jan D. H. Jongbloed; Luc Jordaens; Maarten J. Cramer; Pieter A. Doevendans; Jacques M.T. de Bakker; Arthur A. M. Wilde; J. Peter van Tintelen; Richard N.W. Hauer

Background— Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an autosomal dominant inherited disease with incomplete penetrance and variable expression. Causative mutations in genes encoding 5 desmosomal proteins are found in ≈50% of ARVD/C index patients. Previous genotype-phenotype relation studies involved mainly overt ARVD/C index patients, so follow-up data on relatives are scarce.nnMethods and Results— One hundred forty-nine ARVD/C index patients (111 male patients; age, 49±13 years) according to 2010 Task Force criteria and 302 relatives from 93 families (282 asymptomatic; 135 male patients; age, 44±13 years) were clinically and genetically characterized. DNA analysis comprised sequencing of plakophilin-2 ( PKP2 ), desmocollin-2, desmoglein-2, desmoplakin, and plakoglobin and multiplex ligation-dependent probe amplification to identify large deletions in PKP2. Pathogenic mutations were found in 87 index patients (58%), mainly truncating PKP2 mutations, including 3 cases with multiple mutations. Multiplex ligation-dependent probe amplification revealed 3 PKP2 exon deletions. ARVD/C was diagnosed in 31% of initially asymptomatic mutation-carrying relatives and 5% of initially asymptomatic relatives of index patients without mutation. Prolonged terminal activation duration was observed more than negative T waves in V1 to V3, especially in mutation-carrying relatives <20 years of age. In 45% of screened families, ≥1 affected relatives were identified (90% with mutations).nnConclusions— Pathogenic desmosomal gene mutations, mainly truncating PKP2 mutations, underlie ARVD/C in the majority (58%) of Dutch index patients and even 90% of familial cases. Additional multiplex ligation-dependent probe amplification analysis contributed to discovering pathogenic mutations underlying ARVD/C. Discovering pathogenic mutations in index patients enables those relatives who have a 6-fold increased risk of ARVD/C diagnosis to be identified. Prolonged terminal activation duration seems to be a first sign of ARVD/C in young asymptomatic relatives.nn# Clinical Perspective {#article-title-38}


Human Mutation | 2011

MLL2 mutation spectrum in 45 patients with Kabuki syndrome

Aimee D.C. Paulussen; Alexander P.A. Stegmann; Marinus J. Blok; Demis Tserpelis; Crool Posma-Velter; Yvonne Detisch; Eric Smeets; Annemieke M. A. Wagemans; J Schrander; Marie Jose H. van den Boogaard; Jasper J. van der Smagt; Arie van Haeringen; Irene Stolte-Dijkstra; Wilhelmina S. Kerstjens-Frederikse; Grazia M.S. Mancini; Marja W. Wessels; Raoul C. M. Hennekam; Maaike Vreeburg; Joep Geraedts; Thomy de Ravel; Jean-Pierre Fryns; Hubert J T Smeets; Koenraad Devriendt; Constance T.R.M. Schrander-Stumpel

Kabuki Syndrome (KS) is a rare syndrome characterized by intellectual disability and multiple congenital abnormalities, in particular a distinct dysmorphic facial appearance. KS is caused by mutations in the MLL2 gene, encoding an H3K4 histone methyl transferase which acts as an epigenetic transcriptional activator during growth and development. Direct sequencing of all 54 exons of the MLL2 gene in 45 clinically well‐defined KS patients identified 34 (75.6%) different mutations. One mutation has been described previously, all others are novel. Clinically, all KS patients were sporadic, and mutations were de novo for all 27 families for which both parents were available. We detected nonsense (n=11), frameshift (n=17), splice site (n=4) and missense (n=2) mutations, predicting a high frequency of absent or non‐functional MLL2 protein. Interestingly, both missense mutations located in the C‐terminal conserved functional domains of the protein. Phenotypically our study indicated a statistically significant difference in the presence of a distinct facial appearance (p=0.0143) and growth retardation (p=0.0040) when comparing KS patients with an MLL2 mutation compared to patients without a mutation. Our data double the number of MLL2 mutations in KS reported so far and widen the spectrum of MLL2 mutations and disease mechanisms in KS.


Nature Genetics | 2012

Dominant missense mutations in ABCC9 cause Cantú syndrome

Magdalena Harakalova; Jeske van Harssel; Paulien A. Terhal; Stef van Lieshout; Karen Duran; Ivo Renkens; David J. Amor; Louise C. Wilson; Edwin P. Kirk; Claire Turner; Debbie Shears; Sixto García-Miñaúr; Melissa Lees; Alison Ross; Hanka Venselaar; Gert Vriend; Hiroki Takanari; Martin B. Rook; Marcel A.G. van der Heyden; Folkert W. Asselbergs; Hans M Breur; Marielle Swinkels; Ingrid Scurr; Sarah F. Smithson; Nine V.A.M. Knoers; Jasper J. van der Smagt; Isaac J. Nijman; Wigard P. Kloosterman; Mieke M. van Haelst; Gijs van Haaften

Cantú syndrome is characterized by congenital hypertrichosis, distinctive facial features, osteochondrodysplasia and cardiac defects. By using family-based exome sequencing, we identified a de novo mutation in ABCC9. Subsequently, we discovered novel dominant missense mutations in ABCC9 in 14 of the 16 individuals with Cantú syndrome examined. The ABCC9 protein is part of an ATP-dependent potassium (KATP) channel that couples the metabolic state of a cell with its electrical activity. All mutations altered amino acids in or close to the transmembrane domains of ABCC9. Using electrophysiological measurements, we show that mutations in ABCC9 reduce the ATP-mediated potassium channel inhibition, resulting in channel opening. Moreover, similarities between the phenotype of individuals with Cantú syndrome and side effects from the KATP channel agonist minoxidil indicate that the mutations in ABCC9 result in channel opening. Given the availability of ABCC9 antagonists, our findings may have direct implications for the treatment of individuals with Cantú syndrome.


Journal of Cardiovascular Electrophysiology | 2008

Activation delay and VT parameters in arrhythmogenic right ventricular dysplasia/cardiomyopathy: Toward improvement of diagnostic ECG criteria

Moniek G.P.J. Cox; Marcel R. Nelen; Arthur A.M. Wilde; Ans C.P. Wiesfeld; Jasper J. van der Smagt; Peter Loh; Maarten J. Cramer; Pieter A. Doevendans; J. Peter van Tintelen; Jacques M.T. de Bakker; Richard N.W. Hauer

Introduction: Desmosomal changes, electrical uncoupling, and surviving myocardial bundles embedded in fibrofatty tissue are hallmarks of activation delay in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Currently, generally accepted task force criteria (TFC) are used for clinical diagnosis. We propose additional criteria based on activation delay and ventricular tachycardia (VT) to improve identification of affected individuals.


Circulation-cardiovascular Genetics | 2009

Desmoglein-2 and Desmocollin-2 Mutations in Dutch Arrhythmogenic Right Ventricular Dysplasia/Cardiomypathy Patients Results From a Multicenter Study

Zahurul A. Bhuiyan; Jan D. H. Jongbloed; Jasper J. van der Smagt; Paola M. Lombardi; Ans C.P. Wiesfeld; Marcel R. Nelen; Meyke Schouten; Roselie Jongbloed; Moniek G.P.J. Cox; Marleen van Wolferen; Luz Maria Rodriguez; Isabelle C. Van Gelder; Hennie Bikker; Albert J. H. Suurmeijer; Maarten P. van den Berg; Marcel Mannens; Richard N.W. Hauer; Arthur A.M. Wilde; J. Peter van Tintelen

Background— This study aimed to evaluate the prevalence and type of mutations in the major desmosomal genes, Plakophilin-2 (PKP2), Desmoglein-2 (DSG2), and Desmocollin-2 (DSC2), in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) patients. We also aimed to distinguish relevant clinical and ECG parameters. Methods and Results— Clinical evaluation was performed according to the Task Force Criteria (TFC). We analyzed the genes in (a) 57 patients who fulfilled the ARVD/C TFC (TFC+), (b) 28 patients with probable ARVD/C (1 major and 1 minor, or 3 minor criteria), and (c) 31 patients with 2 minor or 1 major criteria. In the TFC+ ARVD/C group, 23 patients (40%) had PKP2 mutations, 4 (7%) had DSG2 mutations, and 1 patient (2%) carried a mutation in DSC2, whereas 1 patient (2%) had a mutation in both DSG2 and DSC2. Among the DSG2 and DSC2 mutation-positive TFC+ ARVD/C probands, 2 carried compound heterozygous mutations and 1 had digenic mutations. In probable ARVD/C patients and those with 2 minor or 1 major criteria for ARVD/C, mutations were less frequent and they were all heterozygous. Negative T waves in the precordial leads were observed more (P<0.002) among mutation carriers than noncarriers and in particular in PKP2 mutation carriers. Conclusions— Mutations in DSG2 and DSC2 are together less prevalent (10%) than PKP2 mutations (40%) in Dutch TFC+ ARVD/C patients. Interestingly, biallelic or digenic DSC2 and/or DSG2 mutations are frequently identified in TFC+ ARVD/C patients, suggesting that a single mutation is less likely to cause a full-blown ARVD/C phenotype. Negative T waves on ECG were prevalent among mutation carriers (P<0.002).


Circulation | 2009

Dominant-negative ALK2 allele associates with congenital heart defects.

Kelly Smith; Irene C. Joziasse; Sonja Chocron; Maarten van Dinther; Victor Guryev; Manon C. Verhoeven; Holger Rehmann; Jasper J. van der Smagt; Pieter A. Doevendans; Edwin Cuppen; Barbara J.M. Mulder; Peter ten Dijke; Joeroen Bakkers

Background— Serious congenital heart defects occur as a result of improper atrioventricular septum (AVS) development during embryogenesis. Despite extensive knowledge of the genetic control of AVS development, few genetic lesions have been identified that are responsible for AVS-associated congenital heart defects. Methods and Results— We sequenced 32 genes known to be important in AVS development in patients with AVS defects and identified 11 novel coding single-nucleotide polymorphisms that are predicted to impair protein function. We focused on variants identified in the bone morphogenetic protein receptor, ALK2, and subjected 2 identified variants to functional analysis. The coding single-nucleotide polymorphisms R307L and L343P are heterozygous missense substitutions and were each identified in single individuals. The L343P allele had impaired functional activity as measured by in vitro kinase and bone morphogenetic protein–specific transcriptional response assays and dominant-interfering activity in vivo. In vivo analysis of zebrafish embryos injected with ALK2 L343P RNA revealed improper atrioventricular canal formation. Conclusion— These data identify the dominant-negative allele ALK2 L343P in a patient with AVS defects.


European Journal of Medical Genetics | 2010

Four patients with speech delay, seizures and variable corpus callosum thickness sharing a 0.440 Mb deletion in region 1q44 containing the HNRPU gene.

Almuth Caliebe; Hester Y. Kroes; Jasper J. van der Smagt; José I. Martín-Subero; Holger Toennies; Ruben van 't Slot; Rutger A.J. Nievelstein; Hiltrud Muhle; Ulrich Stephani; Karsten Alfke; Irina Stefanova; Yorck Hellenbroich; Gabriele Gillessen-Kaesbach; Ron Hochstenbach; Reiner Siebert; Martin Poot

Structural genome aberrations are frequently associated with highly variable congenital phenotypes involving mental retardation and developmental delay. Although some of these aberrations may result in recognizable phenotypes, a high degree of phenotypic variability often complicates a comprehensive clinical and genetic diagnosis. We describe four patients with overlapping deletions in chromosomal region 1q44, who show developmental delay, in particular of expressive speech, seizures, hypotonia, CNS anomalies, including variable thickness of the abnormal corpus callosum in three of them. High resolution oligonucleotide and SNP array-based segmental aneuploidy profiling showed that these three patients share a 0.440 Mb interstitial deletion, which does not overlap with previously published consensus regions of 1q44 deletions. Two copies of AKT3 and ZNF238, two previously proposed dosage sensitive candidate genes for microcephaly and agenesis of the corpus callosum, were retained in two of our patients. The deletion shared by our patients encompassed the FAM36A, HNRPU, EFCAB2 and KIF26B genes. Since HNRPU is involved in the regulation of embryonic brain development, this represents a novel plausible candidate gene for the combination of developmental delay, speech delay, hypotonia, hypo- or agenesis of the corpus callosum, and seizures in patients with 1q44 deletions. Since only one of the two patients with deletions including the ZNF124 gene showed a vermis hypoplasia, mere hemizygosity for this gene is not sufficient to cause this anomaly. Moreover, to reconcile the variability in the corpus callosum thickness, additional mechanisms, such as unmasking of hemizygous mutations, position effects and possible interactions with other loci need consideration.

Collaboration


Dive into the Jasper J. van der Smagt's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Peter van Tintelen

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ans C.P. Wiesfeld

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jan D. H. Jongbloed

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge